Michelle Steen
About Michelle Steen
Michelle Steen is the Associate Director of Molecular Assay Development, Cell Therapy at Bristol Myers Squibb in Seattle, Washington, with extensive experience in molecular product development and research.
Current Role and Responsibilities
Michelle Steen currently serves as the Associate Director of Molecular Assay Development, Cell Therapy at Bristol Myers Squibb. Based in Seattle, Washington, she oversees the development and advancement of molecular assays. Her role involves coordinating with various teams to ensure the successful development and application of molecular diagnostic tools in cell therapy.
Previous Positions at Adaptive Biotechnologies
Before her current role, Michelle Steen held multiple positions at Adaptive Biotechnologies Corp. She served as Director of Assay Development, Molecular Product Development, and before that she was the Sr. Manager of Assay Development. She has also been a Manager of Development, a Scientist II and I, and a Research Scientist III and II in the Research and Development department. These roles collectively spanned from 2012 to 2021 in Seattle, Washington.
Research Assistant at Stanford University
Michelle Steen gained valuable research experience at Stanford University School of Medicine. She worked as a Research Assistant in the Department of Genetics, Richard M. Myers Lab from 1999 to 2000 and at the Stanford Human Genome Center from 1998 to 1999. This early career experience helped lay the foundation for her expertise in genetics and molecular biology.
Educational Background and Specializations
Michelle Steen holds a PhD in Physiology and Biophysics from the University of Washington, where she also received certificates in Regulatory Affairs and Clinical Trials. She has an MS in Physiological Sciences from the University of Arizona and a BA in Human Biodynamics from the University of California, Berkeley. Her educational background provides a solid foundation for her roles in biotechnology and molecular assay development.
Project Leadership and Commercialization
Michelle Steen has demonstrated significant leadership in the biotechnology field. She led the development of a next-generation sequencing (NGS)-based molecular diagnostic that received FDA clearance and played a key role in the commercialization of CE-Mark molecular diagnostics. Additionally, she has extensive experience launching Laboratory Developed Tests (LDT assays) from concept to market and has managed teams of Ph.D. scientists, fostering high-performance environments.